Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 9676 | 1065 | 26.2 | 61% |
Classes in level above (level 2) |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | CALVERT FORMULA | Author keyword | 13 | 71% | 1% | 10 |
| 2 | CHATELUT FORMULA | Author keyword | 9 | 83% | 0% | 5 |
| 3 | SKI 2053R | Author keyword | 9 | 83% | 0% | 5 |
| 4 | HEPTAPLATIN | Author keyword | 5 | 63% | 0% | 5 |
| 5 | CALVERT | Author keyword | 4 | 75% | 0% | 3 |
| 6 | TOTAL PLATINUM | Author keyword | 4 | 75% | 0% | 3 |
| 7 | NEDAPLATIN | Author keyword | 3 | 14% | 2% | 22 |
| 8 | CAS 146665 77 2 | Author keyword | 3 | 100% | 0% | 3 |
| 9 | CALVERTS FORMULA | Author keyword | 2 | 67% | 0% | 2 |
| 10 | PLATINUM ANTITUMORAL DRUGS | Author keyword | 2 | 67% | 0% | 2 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | CALVERT FORMULA | 13 | 71% | 1% | 10 | Search CALVERT+FORMULA | Search CALVERT+FORMULA |
| 2 | CHATELUT FORMULA | 9 | 83% | 0% | 5 | Search CHATELUT+FORMULA | Search CHATELUT+FORMULA |
| 3 | SKI 2053R | 9 | 83% | 0% | 5 | Search SKI+2053R | Search SKI+2053R |
| 4 | HEPTAPLATIN | 5 | 63% | 0% | 5 | Search HEPTAPLATIN | Search HEPTAPLATIN |
| 5 | CALVERT | 4 | 75% | 0% | 3 | Search CALVERT | Search CALVERT |
| 6 | TOTAL PLATINUM | 4 | 75% | 0% | 3 | Search TOTAL+PLATINUM | Search TOTAL+PLATINUM |
| 7 | NEDAPLATIN | 3 | 14% | 2% | 22 | Search NEDAPLATIN | Search NEDAPLATIN |
| 8 | CAS 146665 77 2 | 3 | 100% | 0% | 3 | Search CAS+146665+77+2 | Search CAS+146665+77+2 |
| 9 | CALVERTS FORMULA | 2 | 67% | 0% | 2 | Search CALVERTS+FORMULA | Search CALVERTS+FORMULA |
| 10 | PLATINUM ANTITUMORAL DRUGS | 2 | 67% | 0% | 2 | Search PLATINUM+ANTITUMORAL+DRUGS | Search PLATINUM+ANTITUMORAL+DRUGS |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | DEPENDENT RENAL INSUFFICIENCY | 21 | 90% | 1% | 9 |
| 2 | INTACT CISPLATIN | 11 | 78% | 1% | 7 |
| 3 | ULTRAFILTERABLE PLATINUM | 9 | 67% | 1% | 8 |
| 4 | MONOHYDRATED CISPLATIN | 8 | 100% | 0% | 5 |
| 5 | PLASMA PLATINUM LEVELS | 6 | 80% | 0% | 4 |
| 6 | PLASMA ULTRAFILTRATE | 5 | 54% | 1% | 7 |
| 7 | UNRESECTABLE TUMORS | 5 | 63% | 0% | 5 |
| 8 | CIS DICHLORODIAMMINEPLATINUMII | 5 | 11% | 4% | 40 |
| 9 | BIOLOGICAL PATIENT CHARACTERISTICS | 4 | 67% | 0% | 4 |
| 10 | CARBOPLATIN PHARMACOKINETICS | 4 | 75% | 0% | 3 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references | % act. ref. to same field |
|---|---|---|---|---|
| Analytical methodologies for the determination of cisplatin | 2008 | 36 | 63 | 59% |
| CLINICAL PHARMACOKINETICS OF CARBOPLATIN | 1991 | 151 | 87 | 69% |
| Clinical pharmacokinetics and dose optimisation of carboplatin | 1997 | 90 | 138 | 43% |
| Analytical Approaches for Assaying Metallodrugs in Biological Samples: Recent Methodological Developments and Future Trends | 2012 | 10 | 131 | 39% |
| The application of inductively coupled plasma mass spectrometry in clinical pharmacological oncology research | 2008 | 48 | 150 | 30% |
| CARBOPLATIN DOSING FOR ADULT JAPANESE PATIENTS | 2014 | 1 | 15 | 60% |
| Platinum speciation used for elucidating activation or inhibition of Pt-containing anti-cancer drugs | 2010 | 30 | 50 | 34% |
| Speciation of platinum compounds: a review of recent applications in studies of platinum anticancer drugs | 2001 | 47 | 20 | 50% |
| Analytical methodologies for metallomics studies of antitumor Pt-containing drugs | 2010 | 53 | 148 | 19% |
| International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency | 2007 | 65 | 192 | 17% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | PHYS STRUCT MOL MAT | 1 | 33% | 0.2% | 2 |
| 2 | CANCEROL IMMUNOGENET | 1 | 50% | 0.1% | 1 |
| 3 | CHARITE VIRCHOW UNIV HOSP | 1 | 50% | 0.1% | 1 |
| 4 | ESCOLA ENFERMAGEM NUTR | 1 | 50% | 0.1% | 1 |
| 5 | GYNE ONCOL | 1 | 50% | 0.1% | 1 |
| 6 | HUNTINGTON DVA MED | 1 | 50% | 0.1% | 1 |
| 7 | MOL MED CORE IL | 1 | 50% | 0.1% | 1 |
| 8 | PHARM ONCOL | 1 | 50% | 0.1% | 1 |
| 9 | PHARMACEUT SCI 332 N LAUDERDALE | 1 | 50% | 0.1% | 1 |
| 10 | PHARMACOL DEV THER EUT | 1 | 50% | 0.1% | 1 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000189441 | NEPHROTOXICITY//SERV FARMACOL TOSSICOL//CISPLATIN NEPHROTOXICITY |
| 2 | 0.0000142848 | PLATINUM BASED DRUG//JM216//PLATINUM COMPLEXES |
| 3 | 0.0000134511 | LIPOSOMAL CISPLATIN//LIPOPLATIN//SPI 077 |
| 4 | 0.0000127736 | CISPLATIN RESISTANCE//PLATINUM DNA ADDUCTS//HUMAN OVARIAN CANCER CELL LINE |
| 5 | 0.0000121913 | ETOPOSIDE PHOSPHATE//ETOPOSIDE//ORAL ETOPOSIDE |
| 6 | 0.0000096670 | PLATINUM RESISTANT//RECURRENT OVARIAN CANCER//PEGYLATED LIPOSOMAL DOXORUBICIN |
| 7 | 0.0000092043 | LOBAPLATIN//AFFILIATED JIANGSU CANC HOSP//PHY906 |
| 8 | 0.0000085578 | FRACTIONATED X IRRADIATION//RAT YOLK SAC TUMOR//DRUG EFFECT ON BRAIN |
| 9 | 0.0000083566 | INTRAPERITONEAL CHEMOTHERAPY//INTRAPERITONEAL//INTRAPERITONEAL THERAPY |
| 10 | 0.0000068313 | DOSE BANDING//CHEMOTHERAPY DOSING//GRANULOCYTE MACROPHAGE PROGENITOR CELLS CFU GM |